{"id":548208,"date":"2021-06-17T18:02:01","date_gmt":"2021-06-17T18:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=548208"},"modified":"2021-06-17T18:02:01","modified_gmt":"2021-06-17T18:02:01","slug":"ornithine-transcarbamylase-deficiency-market-insight-epidemiology-and-market-forecast-analysis-report","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ornithine-transcarbamylase-deficiency-market-insight-epidemiology-and-market-forecast-analysis-report_548208.html","title":{"rendered":"Ornithine Transcarbamylase Deficiency Market Insight, Epidemiology and Market Forecast Analysis Report"},"content":{"rendered":"
\"Ornithine<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Ornithine Transcarbamylase Deficiency Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Ornithine Transcarbamylase Deficiency (OTC Deficiency), historical and forecasted epidemiology as well as the Ornithine Transcarbamylase Deficiency (OTC Deficiency) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

What is Ornithine Transcarbamylase (OTC) Deficiency?<\/strong><\/p>\n

Ornithine transcarbamylase (OTC\/OTCD) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC) and is the only X-linked urea cycle disorder. The disorder that prevents the breakdown and excretion of ammonia; this allows ammonia to rise to toxic levels and affect the central nervous system.<\/p>\n

What is the cause of OTC deficiency?<\/strong><\/p>\n

The underlying cause of OTC deficiency is a gene mutation on the X chromosome and over 100 mutations have been found to result in OTCD.<\/p>\n

What are the symptoms of Ornithine Transcarbamylase (OTC) Deficiency? <\/strong><\/p>\n

OTC deficiency symptoms includes vomiting, refusal to eat, progressive lethargy, and coma. The severity and age of onset of OTC deficiency vary from person to person, even within the same family. Most commonly, symptoms of OTC deficiency begin in infancy (the early-onset form). An infant with OTC deficiency may be lacking energy (lethargic), be unwilling to eat, and have problems with breathing rate or body temperature.<\/p>\n

How is Ornithine Transcarbamylase Deficiency diagnosed? <\/strong><\/p>\n

A diagnosis of OTC deficiency should be considered in any newborn that has an undiagnosed illness characterized by vomiting, progressive lethargy, and irritability. The study of blood plasma and urine is used to differentiate OTC deficiency from other urea cycle disorders. Individuals with OTC deficiency usually have both low levels of citrulline and high glutamine in the blood and high levels of orotic acid in the urine. In rare cases, OTC deficiency may be detected by surgical removal (biopsy) and microscopic examination of tissue samples from the liver, duodenum, and rectum where deficient enzyme activity may be seen. DNA genetic testing is also available to confirm the diagnosis.<\/p>\n

How<\/strong> OTC Deficiency is treated?<\/strong><\/p>\n

OTC deficiency treatment includes hydration, arginine, and hemodialysis. Long-term therapy for OTC deficiency combines dietary restrictions and the stimulation of alternative methods of converting and excreting nitrogen from the body (alternative pathways therapy).<\/p>\n

What are Ornithine Transcarbamylase Deficiency Epidemiology Insights?<\/strong><\/p>\n